Ofloxacin: Why the increased popularity?

Journal of Pharmacy Technology

Volumn 12, Issue 3, 1996, Pages 88-96

  Krop, Lynne C ^a  

^a Bay Pines VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ANTACID AGENT; BACTERIAL DNA; CAFFEINE; CALCIUM CARBONATE; CIPROFLOXACIN; CYCLOSPORIN; DNA TOPOISOMERASE (ATP HYDROLYSING); MAGNESIUM; OFLOXACIN; SUCRALFATE; THEOPHYLLINE; WARFARIN;

AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOECONOMICS; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 0030000495     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512259601200306     Document Type: Review

References (75)

1. Todd PA, Faulds D. Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 1991;42:825-76.
2. Sanders WE. Oral ofloxacin: a critical review of the new drug application. Clin Infect Dis 1992;14:539-54
3. Stratton C. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin Ther 1992;14:348-70.
4. Walker RC, Wright AJ. The fluoroquinolones. Mayo Clin Proc 1991; 66:1249-59.
5. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-94.
6. Just PM. Overview of the fluoroquinolones antibiotics. Pharmacotherapy 1993;13(2 pt 2):4S-17S.
7. Wolfson JS, Hooper DC. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med 1989,87(suppl 6C):31S-6S.
8. Richard P, Delangle MH, Merrien D, Barillé S, Reynaud A, Minozzi C, et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 1994;19:54-9.
9. Rydberg J, Larsson C, Miomer H. Resistance to fluoroquinolones in Pseudomonas aeruginosa and Klebsiella pneumoniae. Scand J Infect Dis 1994;26:317-20.
10. Kresken M, Hafner D, Mittermayer H, Verbist L, Bergogne-Berezin E. Prevalence of fluoroquinolone resistance in Europe. Infection 1994;22(suppl 2).S90-8.
11. Naber KG, Witte W, Bauernfeind A, Wiemann B, Wagenlehner F, Klare I, et al. Clinical significance and spread of fluoroquinolone resistant uropathogen in hospitalized urological patients. Infection 1994;22(suppl 2):S122-7.
12. Gentry LO. Prescribing considerations in fluoroquinolone therapy. Pharmacotherapy 1993;13(2 pt 2):39S-44S.
13. Jones RN, Reller LB, Rosati LA, Erwin ME, Sanchez ML. Ofloxacin, a new broad spectrum fluoroquinolone. Diagn Microbiol Infect Dis 1992;15:425-34.
14. Fuchs PC. In vitro antimicrobial activity and susceptibility testing of ofloxacin. AmJ Med 1989;87(suppl 6C):10S-3S.
15. Hoban DJ, Jones RN, Harrell LJ, Knudson M, Sewell D. The North American component (the United States and Canada) of an international comparative MIC trial monitoring ofloxacin resistance. Diagn Microbiol Infect Dis 1993;17:157-61.
16. Hoban DJ, Jones RN. Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Chemotherapy 1995; 41:34-8.
17. Flor S. Pharmacokinetics of ofloxacin an overview. Am J Med 1989; 87(suppl 6C):24S-30S.
18. Systemic anti-infectives. In: Olin BR, ed. Facts and comparisons. St. Louis: Facts and Comparisons, Inc., 1995:340n-340z.
19. Package insert. Floxin (ofloxacin). Raritan, NJ: McNeil Pharmaceutical, 1995.
20. Package insert. Cipro (ciprofloxacin). West Haven, CT: Miles Inc., 1995.
21. Flor SC, Rogge MC, Chow AT. Bioequivalence of oral and intravenous ofloxacin after multiple dose administration to healthy male volunteers. Antimicrob Agents Chemother 1993;37:1468-72.
22. Watanabe Y, Evert S, Craig W. In-vivo dose-response relationships for ofloxacin versus ciprofloxacm (abstract). Interscience Conference on Antimicrobial Agents and Chemotherapy, October 1992.
23. Echols R, Weinstein MP, O'Keeffe B, Shah A, Heller AH. Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. J Antimicrob Chemother 1994;33:111-8.
24. Ritrovato CA, Deeter RG. Respiratory tract penetration of quinolone antimicrobial: a case in study. Pharmacotherapy 1991;11:38-49.
25. Gerding DN, Hitt JA. Tissue penetration of the new quinolones in humans. Rev Infect Dis 1989;11(suppl 5):S1046-57.
26. Naber KG. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis 1989;11(suppl 5):S1321-35.
27. Corrado ML. Worldwide clinical experience with ofloxacin in urologic cases. Urology 1991;27(suppl):28-32.
28. Cox CE. Ofloxacin in the management of complicated urinary tract infections, including prostatitis. Am J Med 1989;87(suppl 6C):S61-8.
29. Peters HJ. Sequential therapy with ofloxacin in complicated urinary tract infections: a randomized comparative study with ciprofloxacin. Infection 1992;20:172-3.
30. Block JM, Walstad RA, Bjertnaes A, Hafstad PE, Holte M, Otemo I, et al. Ofloxacin versus trimethoprim-sulfamethoxazole in acute cystitis. Drugs 1987;34(suppl):100-6.
31. Hooper DC, Wolfson JS. Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects. Antimicrob Agents Chemother 1989;3:1662-7.
32. Tanphaichitra D, Sahaphong S, Srirmuang S. Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections. Infection 1986;14(suppl 4):S321-3.
33. Remy G, Rouger C, Chavanet P, Bernard E, Dellamonica P, Portier H. Use of ofloxacin for prostatitis. Rev Infect Dis 1988;10(suppl 1):S173-4.
34. Aagared J, Knes J, Madsen PU. Prostatic tissue levels of ofloxacin. Urology 1991:38:380-2.
35. Lutz F. Single-dose efficacy of ofloxacin in uncomplicated gonorrhea. Am J Med 1989;87(suppl 6C):69S-74S.
36. Bloomer R, Bruch K, Close V Ofloxacin in the treatment of gonococcal and chlamydial urethritis. Clin Ther 1988:10:263-5
37. Faro S, Martens MG, Maccato M, Hammill HA, Roberts S, Riddle G. Effectiveness of ofloxacin in the treatment of Chlaimydia trachomatis and Neisseria gonorrhoea cervical infection Am J Obstet Gynecol 1991;164:1380-3.
38. Covino JM, Cummings M, Smith B, Benes S, Draft K, McCormack WM. Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase producing and non-penicillinase producing strains. Antimicrob Agents Chemother 1990;34:148-9.
39. Kitchen VS, Donegan C, Ward H, Thomas B, Harris JRW, Taylor-Robinson D. Comparison of ofloxacin with doxycycline in the treatment of non-gonococcal urethritis and cervical chlamydial infection J Antimicrob Chemother 1990;16:32-5.
40. Mogabgab WJ, Holmes B, Murray M, Beville R, Lutz FB, Tack KJ. Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis. Chemotherapy 1990; 36:70-6.
41. Batteiger BE, Jones RB, White A. Efficacy and safety of ofloxacin in the treatment of non-gonococcal sexually transmitted disease. Am J Med 1989;S7(suppl 6C):75S-7S.
42. Drugs for sexually transmitted diseases. Med Lett 1994;36(913):1-6.
43. Schachter J, Moncada JV. In vitro activity of ofloxacin against Chlamydia trachomatis. Am J Med 1989;87(suppl 6C):14S-6S.
44. Weber JT, Johnson RE. New treatments for Chlamydia trachomatis genital infection. Clin Infect Dis 1995;20(suppl 1):S66-71.
45. Gentry LO, Lipsky B, Farber MO, Tucker B, Rodriguez-Gomez G. Oral ofloxacin therapy for lower respiratory tract infections. South Med J 1992;85:14-8.
46. Cherubin CE, Eng RHK, Smith SM, Tan EN. A comparison of anti-microbial activity of ofloxacin, L-ofloxacin and other oral agents for respiratory pathogens. Diagn Microbiol Infect Dis 1992;15:141-4.
47. Sanders WE, Morris JF, Alessi P, Markris AT, McCloskey RV, Trenholme GM, et al. Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. Am J Med 1991;91:261-6
48. Thys JD, Jacobs F, Motte S. Quinolones in the treatment of lower respiratory tract infections. Rev Infect Dis 1989;1(suppl 5):S1212-9.
49. Dupont HL, Ericson CD, Mathewson JJ, Dupont MW. Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo controlled study. Antimicrob Agents Chemother 1992;36:87-91.
50. Long R, Lishner M, Segev S, Rubinstein E. Ofloxacin and the gastrointestinal tract: a potential role in the treatment of bacterial enteritis. J Antimicrob Chemother 1990;26(suppl D):S45-53.
51. Asperilla MO, Smego RA, Scott LK. Quinolone antibiotics in the treatment of Salmonella infections. Rev Infect Dis 1990;12:873-89.
52. Tiguad S, Lucht F, Pyeramond D, Noel F. Use for ofloxacin for the treatment of enteric infections (letter). Rev Infect Dis 1988;10 (suppl 1):207.
53. Hien TT, Bethell DB, Hoa NTT, Wain J, Diep TS, Phi LT, et al. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 1995;20:917-23.
54. Ellner JJ, Hinman AR, Dooley SW, Fischl MA, Sepkowitz KA, Gold-berger MJ, et al. Tuberculosis symposium: emerging problems and promise. J Infect Dis 1993;168:537-51.
55. Iseman MD. Treatment of multidrug resistant tuberculosis. N Engl J Med 1993;329:784-91.
56. Barnes PF, Barrow SA. Tuberculosis in the 1990s. Ann Intern Med 1993;119:400-10.
57. Yew WW, Kwan SY, Ma WK, Khin MA, Chau PY. In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis- J Antimicrob Chemother 1990;26:227-36.
58. Leysen DC, Haemers A, Pattyn SR. Mycobacteria and the new quinolones. Antimicrob Agents Chemother 1989;33:1-5.
59. Davies S, Sparham PD, Spencer RC. Comparative in vitro activity of five fluoroquinolones against mycobacteria. J Antimicrob Chemother 1987;19:605-9.
60. Berlin GGW, Young LS, Bruckner DA. In vitro activity of six fluorinated quinolones against Mycobactrium tuberculosis. J Antimicrob Chemother 1987;19:611-5.
61. Lenarz T. Chemotherapy of otitis media with ofloxacin. Drugs 1987; 34(suppl 1):139-43.
62. Levy R, Shipitzer T, Shvero J, Pitlik SD. Oral ofloxacin as treatment of malignant external otitis: a study of 17 cases. Laryngo-scope 1990;100:548-51.
63. Lenarz T. Ofloxacin in oral chemotherapy of acute and chronic otitis media. Infection 1986;14(suppl 4):S324-6.
64. Barza M. Pharmacokinetics and efficacy of the new quinolones in infections of the eye, ear, nose and throat Rev Infect Dis 1988;10 (suppl 1)S241-52.
65. Letino JR, Augustinsky JB, Weber TM, Pachucki RT. Therapy of serious skin and soft tissue infections with ofloxacin administered by intravenous and oral route. Chemotherapy 1991;37:70-6.
66. Gentry LO, Rodriquez-Gomez G, Zeluff BJ, Khoshdel A, Price M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med 1989;87(suppl 6C):S57-60.
67. Gentry LO, Rodriquez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother 1991; 35:538-41.
68. Dellamonica P, Bernard E, Etesse H, Garraffo R, Drugeon HB. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1989;8:1024-30.
69. Gentry LO. Oral antimicrobial therapy for osteomyelitis. Ann Intern Med 1991;114:986-97.
70. Berrung SE, Madsen L, Iseman MD, Peloquin CA. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med 1995;151:2206-9.
71. Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 1992;14:272-84.
72. Janknegt R. Drug interactions with quinolones. J Antimicrob Chemother 1990;26(suppl D):7-29.
73. Smith GH. Fluoroquinolones drug-drug interactions. Hosp Pharm 1991;5:41-8.
74. Davies BI, Maesen FPV. Drug interactions with quinolones. Rev Infect Dis 1989;11(suppl 5):S1083-90.
75. Cost item listing 1995. Daldosta, GA: Amerisource, 1995:92,170.